Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

June 2016

Feature

From the Field
A Method of Deriving Estimates of Health State Utilities for Patients With Metastatic Breast Cancer
06/20/2016
Stacie Hudgens, MA
Andrew Briggs, DPhil, MSc
Anna Forsythe, PharmaD, MBA, MSc
Gabriel Tremblay, DBA, MSc
Andrew J Lloyd, DPhil
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
...
06/20/2016
Journal of Clinical Pathways
Research Reports
SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors
06/20/2016
Nancy Ehmke, RN, MN, AOCN
Breck Hunnicutt, RN, BSN, CCRC
Hilary Biddle RN, BSN, CCRC
Christina Zelt, RN, MSN
Brooke Hoverman
Stephanie Trenkner, BS
Carlena Magley, BS
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
...
06/20/2016
Journal of Clinical Pathways

Column

Pharma Insights
Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?
06/20/2016
Rick Lifsitz, MBA
Larry Blandford, PharmD—Column Editor
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Beyond Medication Class: How Specific Should the Clinical Pathway Get?
06/20/2016
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD–Column Editor
Taha Khan, PharmD, RPh
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
...
06/20/2016
Journal of Clinical Pathways

Insights

Interview
The Potentials and Barriers of Precision Medicine in Oncology
06/20/2016
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...
In the...
06/20/2016
Journal of Clinical Pathways
Interview
Reducing Waste in Oncology Drug Use
06/20/2016
  According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs...
  According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs...
...
06/20/2016
Journal of Clinical Pathways

News

Conference Coverage
Perceptions of ICER Reports and Health Technology Assessments in the United States
06/20/2016
JCP Editors
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER Effect,”...
Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER Effect,”...
...
06/20/2016
Journal of Clinical Pathways
Conference Coverage
2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting
06/20/2016
JCP Editors
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...
...
06/20/2016
Journal of Clinical Pathways

Department

Research in Review
Bundled Payments Model Utilizing Clinical Pathways a Success for Hip and Knee Replacements
06/20/2016
JCP Editors
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value...
A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value...
...
06/20/2016
Journal of Clinical Pathways
Research in Review
Rectal Cancer Treatment Utilizing Chemotherapy and Radiation Therapy Improving Over Time
06/20/2016
JCP Editors
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...
...
06/20/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

June 2016 Volume 2

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement